Resources
3 Results (showing 1 - 3)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/3/2023 (updated 3/28/2024)
The Bureau of Justice Assistance and the National Institute of Corrections published the Guidelines for Managing Substance Withdrawal in Jails: A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals to help increase access to evidence-based treatment for individuals with SUD and those who are at risk for overdose. There is a high prevalence of SUD among individuals who are incarcerated. Withdrawal while incarcerated is less discussed, but still poses a risk for individuals. The guidelines were created to help jail administrators protect the health and rights of people incarcerated.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence